4.7 Article

Nigral stimulation for resistant axial motor impairment in Parkinson's disease? A randomized controlled trial

Journal

BRAIN
Volume 136, Issue -, Pages 2098-2108

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/brain/awt122

Keywords

Parkinson's disease; DBS; gait; freezing; subthalamic nucleus

Funding

  1. Eberhard Karls University Tubingen [AKF 259-0-0]
  2. Medtronic Europe Sarl
  3. German Research Council (DFG) [WE5375/1-1, PL 525/1-1, BE4609/1-1, KR2219/2-3, KR2119/8-1]
  4. Medical Faculty of the University of Tubingen [AKF 259-0-0]
  5. Medtronic
  6. Abott Pharmaceutical
  7. UCB
  8. Movement Disorder Society
  9. GlaxoSmithKline
  10. Ipsen Pharmaceuticals
  11. University of Tubingen (AKF) [238-0-0]
  12. Werner Reichardt Centre for Integrative Neuroscience (CIN) [PP2011_11]
  13. Research Grant of the Medical Faculty of the University of Tubingen [AKF 246-0-1]
  14. Bayer Vital
  15. Wilhelm-Schuler-Stiftung
  16. German Research Council [DFG GH 94/2-1, DFG EC 307]
  17. Federal Ministry for Education and Research [BFNT 01GQ0761, BMBF 16SV3783, BMBF 03160064B, BMBF V4UKF014]
  18. European Union [ERC 2276329]
  19. Abbott Pharma
  20. Merz Pharmaceuticals
  21. Ipsen Pharma
  22. Pharm-Allergan
  23. Michael J Fox Foundation
  24. Fritz Thyssen foundation [10.11.2.153]
  25. Federal Ministry for Education and Research [BMBF, NGFNplus] [01GS08134]
  26. UCB Pharma
  27. Cephalon
  28. Takeda Pharmaceuticals

Ask authors/readers for more resources

Gait and balance disturbances typically emerge in advanced Parkinson's disease with generally limited response to dopaminergic medication and subthalamic nucleus deep brain stimulation. Therefore, advanced programming with interleaved pulses was put forward to introduce concomittant nigral stimulation on caudal contacts of a subthalamic lead. Here, we hypothesized that the combined stimulation of subthalamic nucleus and substantia nigra pars reticulata improves axial symptoms compared with standard subthalamic nucleus stimulation. Twelve patients were enrolled in this 2 x 2 cross-over double-blind randomized controlled clinical trial and both the safety and efficacy of combined subthalamic nucleus and substantia nigra pars reticulata stimulation were evaluated compared with standard subthalamic nucleus stimulation. The primary outcome measure was the change of a broad-scaled cumulative axial Unified Parkinson's Disease Rating Scale score (Scale II items 13-15, Scale III items 27-31) at '3-week follow-up'. Secondary outcome measures specifically addressed freezing of gait, balance, quality of life, non-motor symptoms and neuropsychiatric symptoms. For the primary outcome measure no statistically significant improvement was observed for combined subthalamic nucleus and substantia nigra pars reticulata stimulation at the '3-week follow-up'. The secondary endpoints, however, revealed that the combined stimulation of subthalamic nucleus and substantia nigra pars reticulata might specifically improve freezing of gait, whereas balance impairment remained unchanged. The combined stimulation of subthalamic nucleus and substantia nigra pars reticulata was safe, and of note, no clinically relevant neuropsychiatric adverse effect was observed. Patients treated with subthalamic nucleus and substantia nigra pars reticulata stimulation revealed no 'global' effect on axial motor domains. However, this study opens the perspective that concomittant stimulation of the substantia nigra pars reticulata possibly improves otherwise resistant freezing of gait and, therefore, highly warrants a subsequent phase III randomized controlled trial.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available